Clinical Trial: N-Acetylcysteine in Patients With Leptospirosis

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07821853) titled 'N-Acetylcysteine in Patients With Leptospirosis' on Aug. 19.

Brief Summary: The goal of this clinical trial is to learn whether oral N-acetylcysteine (NAC) can reduce markers of kidney tubular injury, oxidative stress, and inflammation in adults with non-severe leptospirosis. The main questions it aims to answer are:

* Does NAC result in a greater reduction in urinary kidney injury molecule-1 (KIM-1) levels from Day 1 to Day 5 compared with placebo?

* Does NAC result in a greater reduction in serum reactive oxygen species (ROS) and C-reactive protein (CRP) levels from Day 1 to Day 5 compared with placebo?

Researchers will compar...